Written on: December 17, 2023 by SprayTM
Oz-UK — a contract research organization based in Chippenham, UK, dedicated to providing pressurized metered dose inhaler (pMDI) and liquid aerosol research and development —has installed a new low-GWP (global warming potential) manufacturing line. The announcement comes ahead of the Kigali Amendment deadline, which urges pharmaceutical companies to phase-down of the use of fluorinated gases (F-gases) by 2047.
The new low-GWP line (funded in part by Oz-UK and in part by grants from Wiltshire Council through the UK Government’s Prosperity Funds) is located in one of Oz-UK’s two custom-built facilities in Chippenham, Wiltshire, and will be operational by July 2024. The new line will add to the current client development services for low-GWP solution and suspension pMDI development programs and will manufacture pMDIs containing HFO-1234ze and HFA-152a propellants and will allow 2.5-10 kilogram batches to be manufactured.
Oz-UK, which already offers formulation development services to the pharmaceutical, biotechnology and cannabinoid industries, is investing in its facilities to keep up with global demand for R&D, formulation and pilot production capabilities.
Oz-UK said it is rapidly investing in its existing facilities and development formulation services to now include 10 liter mixing vessels and Pamasol suspension filling equipment. Additionally, Oz-UK has both a schedule 1 & 2 Controlled Drugs License, enabling pMDI development work for a wide range of active pharmaceutical ingredients (APIs), within a regulated environment.
More info: info@oz-uk-labs.com.
